ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

ODAC Votes 13:0 For Approving Perjeta

September 27, 2013

IOM To Advise Army On Spending $210 Mil. Breast Cancer Money

January 8, 1993

HHA “Investigative Memorandum” Revives Controversy Over AIDS Virus, Royalties

July 1, 1994

NCI Cooperative Group, Cancer Center Trials Listed

September 26, 2008

In Brief: ACCC to Bid On Ovarian Cancer Treatment RFP; Community MDs Handle 90% Of Ovarian Patients

September 5, 1975

A Biostatistics Paper Alleges Potential Harm To Patients In Two Duke Clinical Studies

October 2, 2009